

GEORGIA MEDICAID FEE-FOR-SERVICE HEREDITARY TRANSTHYRETIN AMLOIDOSIS AGENTS PA SUMMARY

Preferred	Non-Preferred
N/A	Tegsedi (inotersen)

LENGTH OF AUTHORIZATION: 1 Year

PA CRITERIA:

Approvable for members 18 years of age or older with a diagnosis of polyneuropathy of hereditary transthyretin (hATTR)-mediated amyloidosis who are stage 1 or 2 and have a transthyretin (TTR) mutation confirmed by genotyping

AND

 When prescribed by or in consultation with a neurologist or physician who specializes in the treatment of hereditary transthyretin (hATTR)-mediated amyloidosis

AND

The prescriber, member and pharmacy are enrolled in the Tegsedi Risk Evaluation and Mitigation Strategy (REMS) program.

EXCEPTIONS:

Exceptions to these conditions of coverage are considered through the prior authorization process by calling **OptumRx at 1-866-525-5827**.

PREFERRED DRUG LIST:

For online access to the Preferred Drug List (PDL), please go to <u>http://dch.georgia.gov/preferred-drug-lists</u>.

PA and APPEAL PROCESS:

 For online access to the PA process, please go to <u>www.dch.georgia.gov/prior-authorization-process-and-criteria</u> and click on Prior Authorization (PA) Request Process Guide.

QUANTITY LEVEL LIMITATIONS:

• For online access to the current Quantity Level Limits (QLL), please go to <u>www.mmis.georgia.gov/portal</u>, highlight Pharmacy and click on <u>Other Documents</u>, then select the most recent quarters QLL List.